2.50
Hdl Handle:
http://hdl.handle.net/10755/157287
Type:
Presentation
Title:
USING F2 ISOPROSTANES TO MEASURE OXIDATIVE STRESS IN CLINICAL POPULATIONS
Abstract:
USING F2 ISOPROSTANES TO MEASURE OXIDATIVE STRESS IN CLINICAL POPULATIONS
Conference Sponsor:Western Institute of Nursing
Conference Year:2010
Author:Moore, Ida M. (Ki), DNS, RN, FAAN
P.I. Institution Name:The University of Arizona
Title:Professor
Contact Address:1305 N. Martin, PO Box 210203, Tucson, AZ, 85721, USA
Co-Authors:Petra Miketova; Marilyn Hockenberry
PURPOSE The purpose is to provide an overview of F2 isoprostanes as a biological measure of oxidative stress, and describe changes in F2 isoprostane concentrations during central nervous system (CNS) treatment with methotrexate for childhood acute lymphoblastic leukemia [ALL]).
Rationale: F2 isoprostanes are stable prostaglandin-like compounds formed from the peroxidation of arachidonic acid (a polyunsaturated free fatty acid that is present in high concentrations in membrane lipids) and are present in detectable quantities in biological tissues and fluids. F2 isoprostane levels have been shown to increase substantially in animal models of oxidant injury, are modulated by endogenous antioxidant status, and are unaffected by the lipid content in diet.
METHODS: CSF samples were obtained from 15 children during the first year of ALL therapy. Samples were collected at the time of ALL diagnosis which was prior to any CNS treatment. Subsequent samples were obtained after 1 intrathecal methotrexate treatment (day 7), during intensive CNS treatment (referred to as consolidation) and during continuation phase of treatment. F2 isoprostanes were measured in 100 ?l of CSF by a competitive enzyme-linked immunoassay (ELISA) kit according to instructions (Oxford Biomedical Research). A standard curve was generated from average replicates of standards ranging in concentration from 0 to 125 picograms/ml.
RESULTS: CSF F2 isoprostane concentrations ranged from 15 to 120 picograms/ml which was within the detection range of the assay and the linear range of the standard curve. Mean F2 isoprostane concentrations increased from diagnosis (33.46 pg/ml) to 50.6 pg/ml after 1 week of ALL therapy, and continued to increase during the consolidation phase of treatment (58.3 pg/ml). The mean concentration of F2 isoprostane remained elevated during the continuation phase of ALL therapy (44.8 pg/ml).
RESULTS: from Kruskal-Wallis One Way ANOVA on Ranks showed significant differences by treatment phase (h = 16.9; df = 3; p < 0.001). Dunn's pairwise multiple comparison procedure showed significant differences between mean F2 isoprostane levels at diagnosis and during consolidation, and between diagnosis and continuation (p < .05).
IMPLICATIONS: Findings suggest that F2 isoprostanes can be used to measure oxidative stress in the brain, and that CNS treatment with methotrexate is associated with increased oxidative stress. F2 isoprostanes can be measured in relatively small sample volumes (100 ?l). If the blood brain barrier is intact, CSF F2 isoprostane concentrations should be specific to oxidative stress in the CNS.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Western Institute of Nursing

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleUSING F2 ISOPROSTANES TO MEASURE OXIDATIVE STRESS IN CLINICAL POPULATIONSen_GB
dc.identifier.urihttp://hdl.handle.net/10755/157287-
dc.description.abstract<table><tr><td colspan="2" class="item-title">USING F2 ISOPROSTANES TO MEASURE OXIDATIVE STRESS IN CLINICAL POPULATIONS</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Western Institute of Nursing</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2010</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Moore, Ida M. (Ki), DNS, RN, FAAN</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">The University of Arizona</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Professor</td></tr><tr class="item-address"><td class="label">Contact Address:</td><td class="value">1305 N. Martin, PO Box 210203, Tucson, AZ, 85721, USA</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">kmoore@nursing.arizona.edu</td></tr><tr class="item-co-authors"><td class="label">Co-Authors:</td><td class="value">Petra Miketova; Marilyn Hockenberry</td></tr><tr><td colspan="2" class="item-abstract">PURPOSE The purpose is to provide an overview of F2 isoprostanes as a biological measure of oxidative stress, and describe changes in F2 isoprostane concentrations during central nervous system (CNS) treatment with methotrexate for childhood acute lymphoblastic leukemia [ALL]). <br/>Rationale: F2 isoprostanes are stable prostaglandin-like compounds formed from the peroxidation of arachidonic acid (a polyunsaturated free fatty acid that is present in high concentrations in membrane lipids) and are present in detectable quantities in biological tissues and fluids. F2 isoprostane levels have been shown to increase substantially in animal models of oxidant injury, are modulated by endogenous antioxidant status, and are unaffected by the lipid content in diet. <br/>METHODS: CSF samples were obtained from 15 children during the first year of ALL therapy. Samples were collected at the time of ALL diagnosis which was prior to any CNS treatment. Subsequent samples were obtained after 1 intrathecal methotrexate treatment (day 7), during intensive CNS treatment (referred to as consolidation) and during continuation phase of treatment. F2 isoprostanes were measured in 100 ?l of CSF by a competitive enzyme-linked immunoassay (ELISA) kit according to instructions (Oxford Biomedical Research). A standard curve was generated from average replicates of standards ranging in concentration from 0 to 125 picograms/ml. <br/>RESULTS: CSF F2 isoprostane concentrations ranged from 15 to 120 picograms/ml which was within the detection range of the assay and the linear range of the standard curve. Mean F2 isoprostane concentrations increased from diagnosis (33.46 pg/ml) to 50.6 pg/ml after 1 week of ALL therapy, and continued to increase during the consolidation phase of treatment (58.3 pg/ml). The mean concentration of F2 isoprostane remained elevated during the continuation phase of ALL therapy (44.8 pg/ml). <br/>RESULTS: from Kruskal-Wallis One Way ANOVA on Ranks showed significant differences by treatment phase (h = 16.9; df = 3; p &lt; 0.001). Dunn's pairwise multiple comparison procedure showed significant differences between mean F2 isoprostane levels at diagnosis and during consolidation, and between diagnosis and continuation (p &lt; .05). <br/>IMPLICATIONS: Findings suggest that F2 isoprostanes can be used to measure oxidative stress in the brain, and that CNS treatment with methotrexate is associated with increased oxidative stress. F2 isoprostanes can be measured in relatively small sample volumes (100 ?l). If the blood brain barrier is intact, CSF F2 isoprostane concentrations should be specific to oxidative stress in the CNS.<br/></td></tr></table>en_GB
dc.date.available2011-10-26T19:44:09Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T19:44:09Z-
dc.description.sponsorshipWestern Institute of Nursingen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.